Capricor: Downgrade To Hold On Deramiocel PDUFA Extension And DMD Change

FDA DecisionDeramiocelNegative

AI Analysis

Summary

Capricor's Deramiocel for DMD has received a PDUFA extension, prompting a downgrade to Hold rating from the analyst. The extension indicates a delay in the FDA's review timeline for the application.

Outcome Details

PDUFA extension

Importance:7/10

Sentiment:

-0.60

PDUFA_ExtensionDeramiocelDMDDowngradeRegulatory_Delay

Related Companies

$CAPR

Read the original article

Published by Seeking Alpha Healthcare on September 3, 2026 5:15 PM

Read Original